Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 5/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | HTR1E | P28566 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 2/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11282279 | 0.92 | MAPT (0.48) | HSD11B1CYP3A4CYP2D6CYP2C9OPRM1 | |
| SCHEMBL4810246 | 0.90 | MAPT (0.47) | HSD11B1OPRM1MAPTHTR1ENPSR1 | |
| SCHEMBL3554737 | 0.81 | HSD11B1 (0.58) | HSD11B1ALDH1A1SMN1; SMN2LMNAHDAC4 | |
| SCHEMBL5379326 | 0.81 | HSD11B1 (0.45) | HSD11B1CYP3A4CYP2D6CYP2C9OPRM1 | |
| SCHEMBL351393 | 0.81 | AKR1C1 (0.55) | HSD11B1CYP3A4CYP2D6CYP2C9OPRM1 | |
| SCHEMBL5644252 | 0.79 | OPRM1 (0.42) | HSD11B1OPRM1HDAC4 | |
| SCHEMBL29473164 | 0.79 | HDAC1 (0.42) | HSD11B1MAPTALDH1A1CES2CES1 | |
| SCHEMBL171875 | 0.79 | LMNA (0.47) | HSD11B1CYP3A4CYP2D6CYP2C9OPRM1 | |
| SCHEMBL17508231 | 0.79 | HSD11B1 (0.46) | HSD11B1CYP3A4CYP2C9OPRM1ALDH1A1 | |
| SCHEMBL838025 | 0.79 | ALDH1A1 (0.55) | HSD11B1CYP3A4MAPTALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044023-B1 | DERIVATIVES OF 1-PHENYL-2-PYRIDYNYL ALKYLENE ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS | CHIESI FARMA SPA (IT) | 2011-01-19 | — | — | EP | disclosed |
| US-7671066-B2 | Derivatives of 1-phenyl-2-pyridynyl alkylene alcohols as phosphodiesterase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2010-03-02 | — | — | US | disclosed |
| EP-2044023-A1 | DERIVATIVES OF 1-PHENYL-2-PYRIDYNYL ALKYLENE ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS | CHIESI FARMACEUTICI S.p.A. (IT) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008006509-A1 | DERIVATIVES OF 1-PHENYL-2-PYRIDYNYL ALKYLENE ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2008-01-17 | — | — | WO | disclosed |
| US-20080015226-A1 | Derivatives of 1-phenyl-2-pyridynyl alkylene alcohols as phosphodiesterase inhibitors | CHIESI FARMACEUTICI S.P.A.. | 2008-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015226-A1 | Derivatives of 1-phenyl-2-pyridynyl alkylene alcohols as phosphodiesterase inhibitors | PDE4A, PDE4B, PDE12 | HSD11B1 107/4885CYP3A4 145/4885CYP2D6 866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.